| 名称 | Taselisib |
| 描述 | Taselisib (GDC-0032) is an orally bioavailable inhibitor of the class I phosphatidylinositol 3-kinase (PI3K) alpha isoform (PIK3CA), with potential antineoplastic activity. |
| 细胞实验 | GDC-0032 is dissolved in DMSO. Cells are seeded in replicates of 6 in 96-well plates with 500 to 5,000 cells/well overnight and then treated with GDC-0032. After 4 days, the media are removed and the cells are fixed with 4% glutaraldehyde for 30 minutes. Fixed cells are stained with 0.1% crystal violet for 2 minutes, then washed, and dissolved in 10% acetic acid. |
| 激酶实验 | Characterization of Biochemical and Cellular Activity in Vitro: Enzymatic activity of the class I PI3K isoforms is measured using a fluorescence polarization assay that monitors formation of the product 3,4,5-inositoltriphosphate molecule as it competes with fluorescently labeled PIP3 for binding to the GRP-1 pleckstrin homology domain protein. An increase in phosphatidyl inositide-3-phosphate product results in a decrease in fluorescence polarization signal as the labeled fluorophore is displaced from the GRP-1 protein binding site. Class I PI3K isoforms are expressed and purified as heterodimeric recombinant proteins. Tetramethylrhodamine-labeled PIP3 (TAMRA-PIP3), di-C8-PIP2, and PIP3 detection reagents are purchased from Echelon Biosciences. PI3Kα is assayed under initial rate conditions in the presence of 10 mM Tris (pH 7.5), 25 μM ATP, 9.75 μM PIP2, 5% glycerol, 4 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, and 2% (v/v) DMSO at 60 ng/mL. After assay for 30 min at 25 °C, reactions are terminated with a final concentration of 9 mM EDTA, 4.5 nM TAMRA-PIP3, and 4.2 μg/mL GRP-1 detector protein before reading fluorescence polarization on an Envision plate reader. IC50 values are calculated from the fit of the dose-response curves to a 4-parameter equation. Each reported value is an average of three experiments, and all have a standard deviation less than one geometric mean. |
| 体外活性 | GDC-0032与氟维司群联用,增强氟维司群活性,导致肿瘤消退和肿瘤生长延迟（91％肿瘤生长抑制（TGI））.此外,GDC-0032与他莫昔芬联用,增强他莫昔芬在体内的效力,GDC-0032的肿瘤生长抑制率为102％.GDC-0032药代动力学大约与剂量成比例并且与时间无关,平均t1/2为40小时. |
| 体内活性 | 临床前期数据表明,GDC-0032具有增加PI3Kα同种型（PIK3CA）突变体和HER2扩增的癌细胞系的活性。GDC-0032抑制MCF7-neo/HER2 细胞增殖,IC50为2.5 nM。GDC-0032是I类PI3Kα,δ和γ同种型的口服生物可利用的,有效的和选择性的抑制剂,相对于PI3Kα同种型,其对PI3Kβ同种型抑制率低30倍。 |
| 存储条件 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| 溶解度 | DMSO : 40 mg/mL (86.86 mM), Heating is recommended.
Ethanol : < 1 mg/mL (insoluble or slightly soluble)
|
| 关键字 | RG7604 | inhibit | Taselisib | Inhibitor | GDC0032 | Phosphoinositide 3-kinase | GDC 0032 | RG 7604 | PI3K |
| 相关产品 | Cyclamic acid sodium | Urea | Benzenesulfonamide | Quercetin | Quercetin Dihydrate | Apilimod | pNNP | Tioxolone | Myricetin | Isoprenaline hydrochloride | Erucic acid | Orthanilamide |
| 相关库 | 抑制剂库 | 经典已知活性库 | 抗癌活性化合物库 | 已知活性化合物库 | 激酶抑制剂库 | 抗衰老化合物库 | 抗肺癌化合物库 | 药物功能重定位化合物库 | 抗癌临床化合物库 | 抗癌药物库 |